| Clinical implications of the intrinsic molecular subtypes of breast cancer A Prat, E Pineda, B Adamo, P Galván, A Fernández, L Gaba, M Díez, ... The Breast 24, S26-S35, 2015 | 1194 | 2015 |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ... NPJ breast cancer 7 (1), 1, 2021 | 392 | 2021 |
| Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy A Prat, C Fan, A Fernández, KA Hoadley, R Martinello, M Vidal, M Viladot, ... BMC medicine 13, 1-11, 2015 | 181 | 2015 |
| HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis F Schettini, T Pascual, B Conte, N Chic, F Brasó-Maristany, P Galván, ... Cancer treatment reviews 84, 101965, 2020 | 123 | 2020 |
| Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer JM Cejalvo, T Pascual, A Fernández-Martínez, F Brasó-Maristany, ... Cancer treatment reviews 67, 63-70, 2018 | 108 | 2018 |
| Survival, pathologic response, and genomics in CALGB 40601 (Alliance), a neoadjuvant phase III trial of paclitaxel-trastuzumab with or without lapatinib in HER2-positive breast … A Fernandez-Martinez, IE Krop, DW Hillman, MY Polley, JS Parker, ... Journal of Clinical Oncology 38 (35), 4184-4193, 2020 | 92 | 2020 |
| CALGB 40603 (Alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple … JH Shepherd, K Ballman, MYC Polley, JD Campbell, C Fan, S Selitsky, ... Journal of Clinical Oncology 40 (12), 1323-1334, 2022 | 80 | 2022 |
| A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer A Abdulla, WM Davis, N Ratnaweera, E Szefer, BB Scott, AYY Lee Thrombosis and haemostasis 120 (04), 702-713, 2020 | 59 | 2020 |
| Outpatient management of pulmonary embolism in cancer: data on a prospective cohort of 138 consecutive patients C Font, A Carmona-Bayonas, A Fernández-Martinez, C Beato, A Vargas, ... Journal of the National Comprehensive Cancer Network 12 (3), 365-373, 2014 | 48 | 2014 |
| Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma F Aya, A Fernandez-Martinez, L Gaba, I Victoria, M Tosca, E Pineda, ... Clinical and Translational Oncology 19, 119-124, 2017 | 33 | 2017 |
| Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2/HER2-positive breast cancer: a correlative … A Fernandez-Martinez, T Pascual, B Singh, P Nuciforo, NU Rashid, ... JAMA oncology 9 (4), 490-499, 2023 | 27 | 2023 |
| Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer T Pascual, G Perrone, S Morales, J de la Haba, M González-Rivera, ... Oncotarget 8 (13), 21930, 2017 | 24 | 2017 |
| Prognostic value of 18F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer M Mayoral, A Fernandez-Martinez, L Vidal, D Fuster, F Aya, J Pavia, ... Revista Española de Medicina Nuclear e Imagen Molecular 35 (2), 88-95, 2016 | 23 | 2016 |
| Different pathological complete response rates according to PAM50 subtype in HER2+ breast cancer patients treated with neoadjuvant pertuzumab/trastuzumab vs. trastuzumab plus … T Díaz-Redondo, R Lavado-Valenzuela, B Jimenez, T Pascual, F Gálvez, ... Frontiers in oncology 9, 1178, 2019 | 17 | 2019 |
| Ipilimumab after progression on anti-PD-1 treatment in advanced melanoma F Aya, L Gaba, I Victoria, A Fernández-Martínez, M Tosca, A Prat, ... Future Oncology 12 (23), 2683-2688, 2016 | 17 | 2016 |
| Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021; 7 (1): 1 F Schettini, N Chic, F Brasó-Maristany, L Paré, T Pascual, B Conte, ... Přejít k původnímu zdroji... Přejít na PubMed, 0 | 17 | |
| A pathology-based combined model to identify PAM50 non-luminal intrinsic disease in hormone receptor-positive HER2-negative breast cancer T Pascual, M Martin, A Fernández-Martínez, L Paré, E Alba, ... Frontiers in oncology 9, 303, 2019 | 15 | 2019 |
| Distribution of the PAM50 breast cancer subtypes within each pathology-based group: a combined analysis of 15,339 patients across 29 studies JM Cejalvo, T Pascual, A Fernández-Martínez, B Adamo, N Chic, M Vidal, ... Annals of Oncology 28, v603, 2017 | 13 | 2017 |
| Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer G Villacampa, NM Tung, S Pernas, L Paré, C Bueno-Muiño, I Echavarría, ... Annals of Oncology 34 (9), 783-795, 2023 | 12 | 2023 |
| Correlation of 18F-FDG uptake on PET/CT with Ki67 immunohistochemistry in pre-treatment epithelial ovarian cancer. M Mayoral, P Paredes, A Saco, P Fuste, P Perlaza, A Tapias, ... Revista Espanola de Medicina Nuclear e Imagen Molecular 37 (2), 80-86, 2017 | 12 | 2017 |
